

AMERICAN VIETNAMESE BIOTECH INC

Separate Financial Statements

Quarter IV 2024



AMERICAN VIETNAMESE BIOTECH INC

4F, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan Phu Ward, District 7, Ho Chi Minh City

INDEX

	Page
REPORT OF THE BOARD OF DIRECTORS	2 - 3
SEPARATE FINANCIAL STATEMENTS QUARTER IV	
Separate balance sheet Quarter IV	4 - 5
Separate business performance report Quarter IV	6
Separate cash flow statement Quarter IV	7
Notes to the Separate Financial Statements Quarter IV	8 - 30

AMERICAN VIETNAMESE BIOTECH INC

4F, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan Phu Ward, District 7, Ho Chi Minh City

REPORT OF THE BOARD OF DIRECTORS

The Board of Directors of American Vietnamese Biotech INC (hereinafter referred to as "the Company") presents its Report and the Company's Separate Financial Statements for the Fourth Quarter.

Company Overview

American vietnamese biotech inc was established and operated under the Business Registration Certificate of Joint Stock Company No. 3800237998, first registered on August 26, 2002, changed for the 23rd time on August 5, 2024, issued by the Business Registration Office of the Department of Planning and Investment of Ho Chi Minh City.

Charter capital : 1.311.056.500.000 VND.

Stock code: AMV.

Number of shares: 131.105.650 shares.

Face value: 10,000 VND.

The Company's head office is located at 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City.

The Company's business lines are medical equipment and medical testing chemicals.

Board of Directors and Management

Members of the Board of Directors and the Board of Management during the accounting period and up to the date of this report include:

Board of Directors

Mr. Nakatani Yoshitaka Chairman of the Board

Mrs. Dang Nhi Nuong Member

Mr. Le Khanh Nguyen Member

Board of Directors

Mrs. Dang Nhi Nuong Director

Legal representative

The legal representative of the Company during the accounting period and up to the time of this report is Ms. Dang Nhi Nuong – Director

The Board of Directors is responsible for preparing the Separate financial statements that give a true and fair view of the Separate financial position, Separate results of operations and Separate cash flows of the Company during the accounting period. In preparing the Separate financial statements for the fourth quarter, the Board of Directors must:

- Select suitable accounting policies and apply them consistently;
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, and all material discrepancies have been presented and explained in the Separate Financial Statements for the fourth quarter;
- Prepare the Separate financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business;

AMERICAN VIETNAMESE BIOTECH INC

4F, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan Phu Ward, District 7, Ho Chi Minh City

REPORT OF THE BOARD OF DIRECTORS

- Establish and implement an effective internal control system to minimize the risk of material misstatement due to fraud or error in the preparation and presentation of the quarterly Separate financial statements. IV .

The Board of Directors is responsible for ensuring that proper accounting records are kept which disclose, with reasonable accuracy at any time, the financial position and performance of the Company and that the accounting records comply with the applicable accounting system. The Board of Directors is also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and the statutory requirements relevant to the preparation and presentation of the Separate Financial Statements. IV .

The Board of Directors confirms that it has complied with the above requirements in preparing the Separate Financial Statements for the quarter. IV .

Approval of Separate Financial Statements

Board of Directors approves the quarterly Separate financial statements IV attached. The Separate financial statements for the fourth quarter have fairly and fairly reflected the Separate financial situation of the Company as of December 31, 2024 , as well as the Separate business results for the quarter . IV and Separate cash flows for the period ended on the same date, in accordance with accounting standards, Vietnamese Enterprise Accounting Regime and legal regulations related to the preparation and presentation of the Separate Financial Statements for the quarter. IV .

On behalf of the Board of Directors



Dang Nhi Nuong

Director

Ho Chi Minh City, January 24 , 2025

AMERICAN VIETNAMESE BIOTECH INC

4F, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan Phu Ward, District 7, Ho Chi Minh City

SEPARATE BALANCE SHEET

As of December 31 , 2024

ASSET	Code	TM	Unit: VND	
			31/12/2024	01/01/2024
A/ CURRENT ASSETS	100		181.703.840.418	320.752.651.952
I/ Cash and cash equivalents	110	5.1	2.123.348.100	6.404.911.296
1. Cash	111		2.123.348.100	6.404.911.296
II/ Short-term financial investment	120		-	-
III/ Short-term receivables	130		169.207.200.937	153.124.423.200
1. Short-term trade receivables	131	5.3	153.330.962.241	39.531.334.576
2. Short-term vendor advance	132	5.4	9.527.923.162	113.153.578.000
3. Other short-term receivables	136	5.5	6.607.640.662	514.885.909
4. Provision for doubtful short-term receivable:	137	5.3	(259.325.128)	(75.375.285)
IV/ Inventory	140	5.6	10.373.291.381	160.972.611.648
1. Inventory	141		10.373.291.381	160.972.611.648
V/ Other current assets	150		-	250.705.808
1. Short-term prepaid expenses	151	5.7	-	29.931.820
2. VAT deductible	152		-	220.773.988
B/ LONG-TERM ASSETS	200		1.505.574.882.958	1.364.943.625.545
II/ Long-term receivables	210		-	-
III/ Fixed assets	220		55.708.295.296	62.694.603.970
1. Tangible fixed assets	221	5.8	26.342.467.158	38.267.230.815
- Original price	222		49.345.390.809	64.268.202.914
- Accumulated depreciation value	223		(23.002.923.651)	(26.000.972.099)
2. Intangible fixed assets	227	5.8	29.365.828.138	24.427.373.155
- Original price	228		50.177.624.939	40.953.427.745
- Accumulated depreciation value	229		(20.811.796.801)	(16.526.054.590)
III/ Investment real estate	230		-	-
IV/ Long-term unfinished assets	240		30.414.773.956	26.588.372.787
1. Cost of unfinished basic construction	242		30.414.773.956	26.588.372.787
V/ Long-term financial investment	250		1.419.438.458.076	1.275.629.485.662
1. Investment in joint ventures	251	5.2	1.284.140.000.000	1.289.040.000.000
2. Investments in associates	252		153.300.000.000	-
3. Provision for long-term financial investments	254		(18.001.541.924)	(13.410.514.338)
VI/ Other long-term assets	260		13.355.630	31.163.126
1. Long-term prepaid expenses	261	5.7	13.355.630	31.163.126
TOTAL ASSETS	270		1.687.278.723.376	1.685.696.277.497

AMERICAN VIETNAMESE BIOTECH INC

4F, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan Phu Ward, District 7, Ho Chi Minh City

SEPARATE BALANCE SHEET

As of December 31 , 2024

CAPITAL SOURCE	Code	TM	Unit: VND	
			31/12/2024	01/01/2024
C/ LIABILITIES PAYABLE	300		123.482.868.408	123.786.163.858
I/ Short-term debt	310		123.482.868.408	123.786.163.858
1. Short-term trade payables	311	5.9	1.149.011.676	6.073.280.479
3. Taxes and other payments to the State	313	5.11	1.457.746.533	6.016.462
4. Payable to workers	314		593.880.249	376.678.179
5. Short-term payable expenses	315		19.725.864.123	9.620.385.088
6. Other short-term payables	319	5.10	75.931.270.000	75.931.270.000
7. Short-term loans and finance leases	320	5.12	24.625.095.827	31.778.533.650
II/ Long-term debt	330		-	-
D/ EQUITY	400		1.563.795.854.968	1.561.910.113.639
\ Equity	410	5.14	1.563.795.854.968	1.561.910.113.639
1. Owner's equity	411		1.311.056.500.000	1.311.056.500.000
'- Common shares with voting rights	411a		1.311.056.500.000	1.311.056.500.000
2. Capital surplus	412		(395.300.000)	(395.300.000)
3. Undistributed profit after tax	421		253.134.654.968	251.248.913.639
- Undistributed profit after tax accumulated to the end of the previous period	421a		251.248.913.639	215.505.662.285
- Undistributed profit after tax this period	421b		1.885.741.329	35.743.251.354
III/ Other funding sources and funds	430		-	-
TOTAL CAPITAL	440		1.687.278.723.376	1.685.696.277.497



Dang Nhi Nuong
Director

Ho Chi Minh City January 24 , 2025

Le Thi Viet Ha
Chief Accountant

Nguyen Minh Hoa
The charist

**SEPARATE BUSINESS PERFORMANCE REPORT FOR THE
FOURTH QUARTER OF 2024**

Unit: VND

Target	Code	Notes	Quarter IV		Accumulated from the beginning	
			This year	Last year	This year	Last year
1. Sales and service revenue	01	6.1	134,542,667,381	18,156,568,583	169,327,403,953	53,332,389,363
2. Revenue deductions	02		-	-	-	3,028,000
3. Net revenue from sales and services	10		134,542,667,381	18,156,568,583	169,327,403,953	53,329,361,363
4. Cost of goods sold	11	6.2	125,187,344,799	16,381,254,875	160,375,561,908	47,115,460,142
5. Gross profit from sales and service provision	20		9,355,322,582	1,775,313,708	8,951,842,045	6,213,901,221
6. Financial revenue	21	6.3	5,000,102,280	12,000,160,093	10,000,513,202	43,090,393,468
7. Financial costs	22	6.4	(42,964,884,273)	(1,268,788,114)	14,548,138,263	8,054,900,630
8. In which: Interest expense	23		1,631,781,902	1,036,262,771	9,957,110,677	4,561,162,077
9. Cost of sales	25	6.5	73,708,308	-	321,072,342	1,380,027,624
10. Business management costs	26	6.6	2,291,665,151	1,134,355,086	5,301,907,527	3,891,466,055
11. Net operating profit	30		54,954,935,676	13,909,906,829	(1,218,762,885)	35,977,900,380
12. Other income	31		3,924,305,575	(2)	3,924,305,575	-
13. Other costs	32	6.7	4,000,000	113,851,812	34,940,246	456,980,057
14. Other profits	40		3,920,305,575	(113,851,814)	3,889,365,329	(456,980,057)
15. Total accounting profit before tax	50		58,875,241,251	13,796,055,015	2,670,602,444	35,520,920,323
16. Current corporate income tax expense	51		784,861,115	-	784,861,115	-
17. Deferred corporate income tax expense	52		-	-	-	-
18. Profit after corporate income tax	60		58,090,380,136	13,796,055,015	1,885,741,329	35,520,920,323

(*): Chỉ tiêu Lãi cơ bản trên cổ phiếu và Lãi suy giảm trên cổ phiếu được trình bày trên Báo cáo tài chính hợp nhất. không trình bày trên Báo cáo tài chính riêng.

Signature

Le Thi Viet Ha
Chief Accountant

Signature

Nguyen Minh Hoa
The chartist



Dang Nhi Nuong
Director

Ho Chi Minh City January 24, 2025

AMERICAN VIETNAMESE BIOTECH INC

4F, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan Phu Ward, District 7, Ho Chi Minh City

SEPARATE STATEMENT OF CASH FLOWS

(By indirect method)

Quarter IV 2024


			Unit: VND	
	Targer	MS	Từ 01/01/2024 đến 31/12/2024	Từ 01/01/2023 đến 31/12/2023
1.	Profit before tax	01	2.670.602.444	35.520.920.323
-	Depreciation of fixed assets and investment real estate	02	9.667.514.548	11.424.411.613
-	Provisions	03	4.774.977.429	3.019.169.159
-	Profit and loss from investment activities	05	(10.000.513.202)	(42.904.983.943)
-	Interest expense	06	9.957.110.677	4.561.162.077
3.	Operating profit before changes in working capital	08	17.069.691.896	11.620.679.229
-	Increase, decrease receivables	09	-26.494.519.127	(34.065.677.588)
-	Increase, decrease inventory	10	150.599.320.267	(14.955.108.735)
-	Increase, decrease in payables (excluding interest payable, corporate income tax payable)	11	10.172.760.715	1.454.909.463
-	Increase, decrease prepaid expenses	12	47.739.316	168.799.346
-	Interest paid	14	(23.631.642)	(2.001.730)
-	Corporate income tax paid	15	(200.000.000)	(1.335.636.262)
	Net cash flow from operating activities	20	151.171.361.425	(37.114.036.277)
1.	Cash spent on purchasing and constructing fixed assets and other long-term assets	21	-	(125.954.545)
2.	Money spent on investment in other entities	25	(153.300.000.000)	(167.690.000.000)
3.	Proceeds from capital investment in other entities	26		138.190.000.000
4.	Interest income, dividends and profits	27	5.000.513.202	43.018.831.824
	Net cash flow from investing activities	30	(148.299.486.798)	13.392.877.279
1.	Loan principal repayment	34	(7.153.437.823)	(4.579.635.855)
	Net cash flow from financing activities	40	(7.153.437.823)	(4.579.635.855)
	Net cash flow during the period	50	(4.281.563.196)	(28.300.794.853)
	Cash and cash equivalents at the beginning of the period	60	6.404.911.296	34.705.706.149
	Ảnh hưởng của thay đổi tỷ giá hối đoái quy đổi ngoại tệ	61		
	Cash and cash equivalents at the end of the period	70	2.123.348.100	6.404.911.296



Dang Nhi Nuong
Director

Ho Chi Minh City January 24, 2025


Le Thi Viet Ha
Chief Accountant


Nguyen Minh Hoa
The chartist

AMERICAN VIETNAMESE BIOTECH INC

4F, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan Phu Ward, District 7, Ho Chi Minh City

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

These explanatory notes are an integral part of and should be read in conjunction with the accompanying separate financial statements.

1. OPERATIONAL CHARACTERISTICS

Form of Capital Ownershi

Amvi Biotec Inc. is established and operating under the Enterprise Registration Certificate No. 3800237998, initially issued on August 26th, 2002, and amended for the 23rd time on August 5th, 2024, by the Business Registration Office of the Department of Planning and Investment of Ho Chi Minh City.

- **Charter Capital:** 1.311.056.500.000 VND
- **Stock Code:** AMV
- **Number of Shares:** 131.105.650 shares
- **Par Value:** 10.000 VND per share
- **Head Office:** 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan Phu Ward, District 7, Ho Chi Minh City, Vietnam.

Business Areas

The Company operates in the field of medical equipment and medical testing chemicals.

Business Activities

Retail of pharmaceuticals, medical instruments, cosmetics, and hygiene products in specialized stores. Specifically:

Trading pharmaceuticals, medical equipment, instruments, and medical testing chemicals.

Manufacturing medical, dental, orthopedic, and rehabilitation equipment. Specifically: manufacturing medical testing instruments.

Manufacturing pharmaceuticals, chemical drugs, and medicinal materials. Specifically: manufacturing and trading vaccines and medical biological products.

Real estate business, including ownership, usage rights, or leasing. Specifically: real estate trading.

Manufacturing cosmetics, soaps, detergents, polishes, and cleaning products.

Agency, brokerage, and auction activities. Specifically: consignment agency. Manufacturing plastic products.

Asset holding company activities. Specifically: financial investment.

Other professional, scientific, and technological activities not classified elsewhere. Specifically: technology transfer.

Normal Production and Business Cycle

The Company's normal production and business cycle does not exceed 12 months.

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

1.1 Statement on the Comparability of Information in the Financial Statements

The comparative figures of the previous period are consistent and comparable with those of the current period.

1.2 Company Structure

Company	Place of Establishment	Ownership Percentage (%)	Voting Rights	Core Business Activities
Directly Owned Subsidiaries				
1. Viet My Hospital Investment Joint Stock Company	No. 307 Nguyen Du Extended Street, Nong Trang Ward, Viet Tri City, Phu Tho Province, Vietnam	83,33	83,33	Wholesale of pharmaceuticals and medical instruments; wholesale of machinery and medical equipment.
2. Ha Long Kyoto Technology Development Joint Stock Company Kyoto	Lot A15, Nam Son Industrial Cluster, Nam Son Commune, Ba Che District, Quang Ninh Province, Vietnam	99	99	Manufacturing pharmaceuticals, chemical drugs, and medicinal materials; manufacturing ovens, kilns, and furnaces.
3. Bai Chay Kyoto Clinic Joint Stock Company	Group 4, Area 4, Bai Chay Town, Ha Long City, Quang Ninh Province, Vietnam	98	98	General and specialized clinics.
4. Song Hau New Technology Application Research Joint Stock Company	Song Hau Industrial Zone – Phase 1, Dong Phu Commune, Chau Thanh District, Hau Giang Province, Vietnam	98	98	Manufacturing ovens, kilns, and furnaces.
5. Vietnam National Software Manufacturing Joint Stock Company	36 BT5, Phap Van - Tu Hiep Urban Area, Hoang Liet Ward, Hoang Mai District, Hanoi City, Vietnam	98	98	Computer programming.
6. Ha Dong Clinic Joint Stock Company	3rd Floor, No. 1 Phuc Thinh, Kien Hung Ward, Ha Dong District, Hanoi City, Vietnam	98	98	General, specialized, and dental clinics.
7. Hoa Binh Clinic Joint Stock Company	No. 83 Cu Chinh Lan Street, Dong Tien Ward, Hoa Binh City, Hoa Binh Province, Vietnam	98	98	General, specialized, and dental clinics.
8. Viet Tri Clinic Joint Stock Company	No. 307 Nguyen Du Extended Street, Nong Trang Ward, Viet Tri City, Phu Tho Province, Vietnam	98	98	General, specialized, and dental clinics.
9. Gia Lam High-Tech Clinic Joint Stock Company	18 BT5, Phap Van - Tu Hiep Urban Area, Hoang Liet Ward, Hoang Mai District, Hanoi City, Vietnam	98	98	General, specialized, and dental clinics.

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

10. Can Tho Medicare Clinic Joint Stock Company	No. 408 Nguyen Van Cu Street, An Binh Ward, Ninh Kieu District, Can Tho City, Vietnam	98	98	General, specialized, and dental clinics.
11. Hau Giang Medicare Clinic Joint Stock Company	No. 16, 1st Floor, Street No. 14, Area 4, Ward III, Vi Thanh City, Hau Giang Province, Vietnam	98	98	General, specialized, and dental clinics.
12. Soc Trang Medicare Clinic Joint Stock Company	1st Floor, No. 438 Le Duan Street, Quarter 4, Ward 4, Soc Trang City, Soc Trang Province, Vietnam 4o	98	98	General, specialized, and dental clinics.
13. Nga Bay Medicare Clinic Joint Stock Company	No. 222, 30/4 Street, Area 5, Lai Hieu Ward, Nga Bay City, Hau Giang Province, Vietnam	98	98	General, specialized, and dental clinics.
14. Leopard Solution Joint Stock Company	No. 34, Street 79, Dinh Hamlet, Tan Phu Trung Commune, Cu Chi District, Ho Chi Minh City, Vietnam	75	75	□ Computer programming.
Indirectly Owned Subsidiaries				
1. Tan Thoi Hiep Medicare Clinic Joint Stock Company	402 Tan Thoi Hiep 07, Quarter 7, Tan Thoi Hiep Ward, District 12, Ho Chi Minh City, Vietnam	96,04	96,04	General, specialized, and dental clinics.
2. Nha Be Medicare Clinic Joint Stock Company	568 Le Van Luong, Hamlet 3, Phuoc Kien Commune, Nha Be District, Ho Chi Minh City, Vietnam	96,04	96,04	General, specialized, and dental clinics.
3. Vinh Yen Famicare Joint Stock Company	2nd Floor, No. 79 Ba Trieu Street, Lien Bao Ward, Vinh Yen City, Vinh Phuc Province, Vietnam	88,2	88,2	General, specialized, and dental clinics.
Investment in associates				
1. Huu Nghi Medicare Clinic Joint Stock Company	No. 179 Giai Phong Street, Dong Tam Ward, Hai Ba Trung District, Hanoi City, Vietnam	49	49	General, specialized, and dental clinics.
2. Ninh Binh Medicare Clinic Joint Stock Company	No. 128 Tue Tinh Street, Nam Thanh Ward, Ninh Binh City, Ninh Binh Province, Vietnam	49	49	General, specialized, and dental clinics.
3. Golab Phap Van Testing Center Joint Stock Company	1st Floor, Lot BT 5, No. 17 Phap Van - Tu Hiep New Urban Area, Hoang Liet Ward, Hoang Mai District, Hanoi City, Vietnam	35	35	General, specialized, and dental clinics.

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

4. Famicare Phap Van Joint Stock Company	1st Floor, Lot BT 5, No. 18 Phap Van - Tu Hiep New Urban Area, Hoang Liet Ward, Hoang Mai District, Hanoi City, Vietnam	35	35	General, specialized, and dental clinics.
5. Golab Go Vap Testing Center Joint Stock Company	755 Nguyen Kiem Street, Ward 3, Go Vap District, Ho Chi Minh City, Vietnam	35	35	General, specialized, and dental clinics.
6. Nghe An Clinic Joint Stock Company	No. 22 Ho Tong Thoc Street, Hamlet 15, Nghi Phu Commune, Vinh City, Nghe An Province, Vietnam	35	35	General, specialized, and dental clinics.
7. Ba Dinh Clinic Joint Stock Company	37A Doc Phu San, De La Thanh Street, Ngoc Khanh Ward, Ba Dinh District, Hanoi City, Vietnam	35	35	General, specialized, and dental clinics.
8. Golab Bac Lieu Testing Center Joint Stock Company	Ground Floor, No. 210 Ba Trieu Street, Ward 3, Bac Lieu City, Bac Lieu Province, Vietnam	35	35	General, specialized, and dental clinics.
9. Golab Binh Duong Testing Center Joint Stock Company	634 Binh Duong Boulevard, Hiep Thanh Ward, Thu Dau Mot City, Binh Duong Province, Vietnam	35	35	General, specialized, and dental clinics.
10. Tuyen Quang Famicare Joint Stock Company	2nd Floor, No. 23 Hoa Lu Street, Group 01, Phan Thiet Ward, Tuyen Quang City, Tuyen Quang Province, Vietnam	35	35	General, specialized, and dental clinics.
11. To Hien Thanh Medicare Clinic Joint Stock Company	1st Floor, No. 9 To Hien Thanh Street, Ward 4, Vung Tau City, Ba Ria-Vung Tau Province, Vietnam	49	49	General, specialized, and dental clinics.
12. Golab Tien Giang Testing Center Joint Stock Company	368A Phuoc Hoa Hamlet, Phuoc Thanh Commune, My Tho City, Tien Giang Province, Vietnam	35	35	General, specialized, and dental clinics.

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

2. FISCAL YEAR AND CURRENCY USED IN ACCOUNTING

The Company's fiscal year begins on January 1st and ends on December 31st each year. The currency used in accounting records is the Vietnamese Dong (VND).

3. ACCOUNTING STANDARDS AND POLICIES APPLIED

3.1 Accounting Policies Applied

The Company applies the accounting regime issued under Circular No. 200/2014/TT-BTC, which provides guidance on corporate accounting regimes dated December 22, 2014, as amended and supplemented by Circular No. 75/2015/TT-BTC dated May 18, 2015, and Circular No. 53/2016/TT-BTC dated March 21, 2016, issued by the Ministry of Finance.

3.2 Statement of Compliance with Accounting Standards and Policies

The Company has applied the Vietnamese Accounting Standards (VAS) and the relevant guidance documents issued by the Government. The separate financial statements have been prepared and presented in accordance with all applicable regulations, standards, and circulars guiding the implementation of the accounting regime currently in effect.

3.3 Accounting Method Applied

The Company applies the general journal accounting method.

4. ACCOUNTING POLICIES APPLIED

4.1 Basis for Preparing Separate Financial Statements

The separate financial statements are prepared on an accrual basis (except for information related to cash flows).

4.2 Cash and Cash Equivalents

Cash includes cash on hand, demand deposits, term deposits, cash in transit, and monetary gold. Cash equivalents are short-term investments with a maturity of no more than three months from the date of investment, which are easily convertible into a known amount of cash and carry minimal risk of changes in value at the reporting date.

4.3 Financial Investments

Investments in Subsidiaries

Subsidiaries are enterprises controlled by the Company. Control is achieved when the Company has the ability to direct the financial and operational policies of the investee to derive economic benefits from its activities.

Investments in subsidiaries are initially recognized at cost, which includes the purchase price or capital contribution and any directly attributable costs related to the investment. For non-monetary asset investments, the investment cost is recognized at the fair value of the non-monetary asset at the time of the transaction.

Dividends and profits from periods prior to the acquisition of the investment are accounted for as a reduction in the investment value. Dividends and profits from periods after the acquisition are

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

recognized as revenue. Dividends received in the form of shares are only tracked as an increase in the number of shares, without recording the value of the shares received.

Provisions for losses on investments in subsidiaries are recognized when the subsidiary incurs losses. The provision is calculated as the difference between the actual contributed capital and the actual equity of the subsidiary, multiplied by the Company's ownership percentage. If the subsidiary is required to prepare Separate financial statements, the basis for determining provisions for losses will be the Separate financial statements.

Increases or decreases in provisions for losses on investments in subsidiaries at the end of the financial year are recognized in financial expenses.

4.4 Receivables

Receivables are presented at book value, net of provisions for doubtful debts.

Receivables are categorized as customer receivables, internal receivables, and other receivables, based on the following principles:

- **Customer Receivables:** Represent trade receivables arising from transactions of a buy-sell nature between the Company and independent buyers, including receivables from entrusted export sales.
- **Internal Receivables:** Represent receivables from dependent entities without independent legal status.
- **Other Receivables:** Represent non-trade receivables unrelated to buy-sell transactions.

Provision for Doubtful Debts

Provisions for doubtful debts are established for each specific receivable based on the overdue age of the debt or the estimated loss that may occur. Specifically:

- For overdue debts:
 - 30% of the value for receivables overdue from 6 months to less than 1 year.
 - 50% of the value for receivables overdue from 1 year to less than 2 years.
 - 70% of the value for receivables overdue from 2 years to less than 3 years.
 - 100% of the value for receivables overdue for 3 years or more.
- For receivables not yet overdue but deemed unlikely to be collected, provisions are established based on the expected loss.

Changes in provisions for doubtful debts at the financial year-end are recognized in administrative expenses.

4.5 Inventories

Inventories are recognized at the lower of cost or net realizable value.

- **Cost of Inventories:** Includes purchase costs, processing costs, and other directly related costs incurred to bring the inventory to its current location and condition.

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

- **Net Realizable Value:** The estimated selling price in the ordinary course of business, less estimated costs of completion and costs to sell.

Inventory valuation is calculated using the weighted average method and accounted for under the perpetual inventory system.

Provision for Inventory Devaluation

Provisions for inventory devaluation are established for each inventory item with a cost exceeding its net realizable value. Changes in provisions for inventory devaluation at the end of the financial year are recognized in the cost of goods sold.

4.6 Fixed Assets and Depreciation

Fixed assets, both tangible and intangible, are recognized at historical cost. During use, they are accounted for at historical cost, accumulated depreciation, and net book value.

- **Historical Cost:** Includes all costs incurred to acquire the fixed asset and bring it to a ready-to-use condition.
- Subsequent costs are capitalized only if they are certain to increase future economic benefits from the use of the asset. Otherwise, they are recognized as expenses in the current period.

When a fixed asset is sold or disposed of, its historical cost and accumulated depreciation are derecognized, and any resulting gain or loss is recognized in the income statement.

Depreciation is calculated on a straight-line basis over the estimated useful life of the asset, in accordance with Circular No. 45/2013/TT-BTC dated April 25, 2013, as amended and supplemented by Circular No. 147/2016/TT-BTC dated October 13, 2016, and Circular No. 28/2017/TT-BTC dated April 12, 2017, on the management, use, and depreciation of fixed assets.

4.7 Prepaid Expenses

Prepaid expenses include short-term or long-term prepaid expenses recorded in the balance sheet and are allocated over the periods that match the economic benefits generated from such expenses.

4.8 Liabilities and Accrued Expenses

Liabilities and accrued expenses are recognized as the amounts payable in the future for goods and services already received. Accrued expenses are recorded based on reasonable estimates of the amounts payable.

Classification of Payables

- **Trade Payables:** Reflects amounts payable for the purchase of goods, services, or assets to independent suppliers, including payables for imports through consignment agents.
- **Accrued Expenses:** Reflects amounts payable for goods or services received from suppliers or delivered to customers but not yet paid due to the absence of invoices or sufficient accounting documentation, including accrued wages and anticipated production/business expenses.
- **Internal Payables:** Reflects payables between parent entities and dependent sub-entities without independent legal status.
- **Other Payables:** Reflects non-commercial payables unrelated to the purchase, sale, or provision of goods and services.

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

4.9 Borrowings and Financial Lease Liabilities

Loans are tracked by lender, loan agreements, and repayment terms. In the case of foreign currency loans, detailed tracking is conducted in the original currency.

4.10 Borrowing Costs

Borrowing costs include loan interest and other directly related expenses. Borrowing costs are recognized as expenses when incurred.

Borrowing costs directly attributable to the construction or production of an asset requiring an extended period (over 12 months) for intended use or sale are capitalized. For loans exclusively financing the construction of fixed assets or investment properties, interest is capitalized even when the construction period is less than 12 months. Any temporary income earned from the interim investment of loans is deducted from the asset's initial cost.

For general-purpose loans partially used for construction or production, capitalized borrowing costs are calculated based on a weighted average capitalization rate applied to cumulative expenditures. The capitalization rate is determined by the weighted average interest rate on outstanding loans, excluding specific-purpose loans for a particular asset.

4.11 Equity

Owner's Capital Contribution

Owner's capital contributions are recorded based on the actual capital contributed by shareholders.

4.12 Profit Distribution

Post-tax profits are distributed to shareholders after the establishment of reserves according to the Company's charter, legal regulations, and approval by the General Meeting of Shareholders.

4.13 Revenue and Income

Sales Revenue

Sales revenue is recognized when the following conditions are met:

- Substantial risks and rewards associated with ownership of the goods have been transferred to the buyer.
- The Company no longer retains managerial control or ownership of the goods.
- Revenue can be reliably measured.
- Economic benefits from the transaction are probable.
- Costs related to the transaction can be identified.

Service Revenue

Service revenue is recognized when the transaction outcome can be reliably measured. For services spanning multiple periods, revenue is recognized based on the work completed as of the balance sheet date, meeting the following conditions:

- Revenue is reliably measurable.
- Economic benefits are probable.

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

- The portion of work completed by the balance sheet date is identifiable.
- Costs incurred and expected to complete the transaction are measurable.

Completed work is determined using the percentage-of-completion method.

Financial Income

Financial income, including interest, royalties, dividends, profit shares, and other financial revenue, is recognized when the following conditions are met:

- Economic benefits are probable.
- Revenue can be reliably measured.

Dividends and profit shares are recognized when the Company has the right to receive them. Dividends received in shares are only tracked by the increase in the number of shares without recognizing their value as financial income.

Interest income is accrued based on the outstanding balance and the effective interest rate for each period.

4.14 Corporate Income Tax

Current Tax

Current tax is calculated based on taxable income, which differs from accounting profit due to adjustments for temporary differences, non-deductible expenses, tax-exempt income, and losses carried forward.

4.15 Related Parties

A party is considered related if it has control or significant influence over the other in financial and operational decision-making. Related parties include:

- Entities directly or indirectly controlling, controlled by, or under common control with the Company, including parent companies, subsidiaries, and associates.
- Individuals directly or indirectly holding voting rights in the Company with significant influence, key management personnel, and their close family members.
- Entities significantly influenced by the individuals mentioned above, either directly or indirectly.

5. ADDITIONAL INFORMATION ON ITEMS PRESENTED IN THE SEPARATE BALANCE SHEET

5.1 Cash and Cash Equivalents

AMERICAN VIETNAMESE BIOTECH INC

4F, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan Phu Ward, District 7, Ho Chi Minh City

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

	<u>31/12/2024</u> <i>VND</i>	<u>01/01/2024</u> <i>VND</i>
Cash	290.950.121	4.763.319.595
Non-term bank deposits	<u>1.832.397.979</u>	<u>1.641.591.701</u>
Add	<u>2.123.348.100</u>	<u>6.404.911.296</u>

AMERICAN VIETNAMESE BIOTECH INC

4F, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan Phu Ward, District 7, Ho Chi Minh City

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

5.2 Financial investment

	31/12/2024			01/01/2024		
	Original Price VND	Contingency cost	Reasonable price VND	Original Price VND	Reasonable price VND	Reasonable price VND
Invest in Subsidiaries	1.284.140.000.000	(17.355.115.305)	1.284.140.000.000	1.284.140.000.000	(13.290.924.002)	1.284.140.000.000
Viet My Hospital Investment JSC	250.000.000.000	(17.154.406.526)	250.000.000.000	250.000.000.000	(8.429.639.324)	250.000.000.000
Ha Long Kyoto.,JSC	108.900.000.000	(200.708.779)	108.900.000.000	108.900.000.000	(58.454.016)	108.900.000.000
Kyoto fire clinic joint stock company	49.000.000.000	-	49.000.000.000	49.000.000.000	(1.019.226.739)	49.000.000.000
Song hau new technology application joint stock company	147.000.000.000	-	147.000.000.000	147.000.000.000	-	147.000.000.000
Vietnam Nation Software Production JSC	29.400.000.000	-	29.400.000.000	29.400.000.000	-	29.400.000.000
Ha Dong Clinic JSC.	77.420.000.000	-	77.420.000.000	77.420.000.000	(981.100.857)	77.420.000.000
Hoa Binh Clinic JSC.	122.500.000.000	-	122.500.000.000	122.500.000.000	(1.037.005.209)	122.500.000.000
Viet Tri Clinic JSC	106.820.000.000	-	106.820.000.000	106.820.000.000	(3.475.927)	106.820.000.000
Gia Lam High-tech Clinic JSC.	77.420.000.000	-	77.420.000.000	77.420.000.000	(759.111.361)	77.420.000.000
Can Tho MEDICARE Clinic JSC.	77.420.000.000	-	77.420.000.000	77.420.000.000	(434.480.816)	77.420.000.000
Hau Giang MEDICARE Clinic JSC.	77.420.000.000	-	77.420.000.000	77.420.000.000	(164.978.524)	77.420.000.000
Soc Trang MEDICARE Clinic JSC.	77.420.000.000	-	77.420.000.000	77.420.000.000	(403.451.229)	77.420.000.000
Nga Bay MEDICARE Clinic JSC.	77.420.000.000	-	77.420.000.000	77.420.000.000	-	77.420.000.000
LEOPARD SOLUTIONS JSC	6.000.000.000	-	6.000.000.000	6.000.000.000	-	6.000.000.000
To Hien Thanh MEDICARE Clinic JSC.	-	-	-	4.900.000.000	(119.590.336)	4.900.000.000

AMERICAN VIETNAMESE BIOTECH INC

4F, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan Phu Ward, District 7, Ho Chi Minh City

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

Investment in joint ventures and assoc	153.300.000.000	(646.426.617)	153.300.000.000	-
Huu Nghi MEDICARE Clinic JSC.	14.700.000.000	(116.686.997)	14.700.000.000	-
Ninh Binh MEDICARE Clinic JSC.	14.700.000.000	(66.206.661)	14.700.000.000	-
Golab Phap Van test center jsc	10.500.000.000	(31.339.259)	10.500.000.000	-
Famicare Phap Van jsc	10.500.000.000	(19.927.589)	10.500.000.000	-
Golab Go Vap test center jsc	10.500.000.000	(29.123.121)	10.500.000.000	-
Nghe An Clinic JSC	10.500.000.000	(35.878.195)	10.500.000.000	-
Ba Dinh Clinic JSC	10.500.000.000	(230.055.034)	10.500.000.000	-
Golab Bac Lieu test center jsc	10.500.000.000	(33.757.173)	10.500.000.000	-
Golab Binh Duong test center jsc	10.500.000.000	(12.406.284)	10.500.000.000	-
Famicare Tuyen Quang jsc	10.500.000.000	(21.370.127)	10.500.000.000	-
Golab Tien Giang test center jsc	10.500.000.000	(22.457.100)	10.500.000.000	-
Golab Ha Giang test center jsc	14.700.000.000	(3.748.697)	14.700.000.000	-
To Hien Thanh medicare clinic jsc	14.700.000.000	(23.470.380)	14.700.000.000	-
Add	1.437.440.000.000	(18.001.541.922)	1.437.440.000.000	1.289.040.000.000
				(13.410.514.338)
				1.289.040.000.000

AMERICAN VIETNAMESE BIOTECH INC

4F, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan Phu Ward, District 7, Ho Chi Minh City

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

5.3 Short-term trade receivables

	31/12/2024		01/01/2024	
	Value VND	Contingency VND	Value VND	Contingency VND
- Can Tho Environment and test center Joint Stock Company	45.502.587.900	-	-	-
Good server technology.,jsc	1.993.625.600	-	-	-
Ha Cuong trading investment company limited	-	-	6.747.955.200	-
Phu Tho Province Obstetrics and Pediatics Hospital Joint Stock Company	250.799.400	-	1.667.033.839	-
- G7 High Technology Joint Stock Company	-	-	18.370.000.000	-
- Japan Medical Equipment Co., Ltd.	-	-	8.642.123.175	-
- Lou Investment Joint Stock Company	18.302.003.421	-	-	-
- Advance payments to other vendors	87.281.945.920	(259.325.128)	4.104.222.362	(75.375.285)
Add	153.330.962.241	(259.325.128)	39.531.334.576	(75.375.285)

5.4 Short-term vendor advance

	31/12/2024		01/01/2024	
	Value VND	Preventive VND	Value VND	Preventive VND
- High-tech Medical Environment Company Limited	-	-	2.099.000.000	-
- Can Tho High-Tech Investment Joint Stock Company	-	-	20.000.000.000	-
Nha Trang Medical High Technology Application Joint Stock Company	5.000.000.000	-	45.000.000.000	-
Viet Tri Clinic JSC	-	-	46.000.000.000	-
Japan kanpeki jsc	3.773.136.374	-	-	-
- Advance payments to other vendors	754.786.788	-	54.578.000	-
Add	9.527.923.162	-	113.153.578.000	-

5.5 Other receivables

5.5.1 Other short-term receivables

AMERICAN VIETNAMESE BIOTECH INC

4F, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan Phu Ward, District 7, Ho Chi Minh City

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

	31/12/2024		01/01/2024	
	Value VND	Preventive VND	Value VND	Preventive VND
Related party transactions	-	-	-	-
Vietnam Nation Software Production JSC	5.000.000.000	-	-	-
Golab Binh Duong test center jsc	500.000.000	-	-	-
Other receivables	1.107.640.662	-	514.885.909	-
	937.864.916	-	332.053.447	-
Deposit, bet				
Advance	169.775.746	-	181.620.350	-
Other receivables	-	-	1.212.112	-
Add	6.607.640.662	-	514.885.909	-

5.6 Inventory

	31/12/2024		01/01/2024	
	Original price VND	Preventive VND	Original price VND	Preventive VND
Goods	10.373.291.381	-	160.972.611.648	-
Add	10.373.291.381	-	160.972.611.648	-

5.7 Prepaid expenses

a) Short-term

	31/12/2024 VND	01/01/2024 VND
Other Expenses	-	29.931.820
Add	-	29.931.820

b) Long-term

	31/12/2024 VND	01/01/2024 VND
Allocated Tools and Supplies	13.355.630	31.163.126
Add	13.355.630	31.163.126

5.8 Increase or decrease in fixed assets

5.8.1 Increase or decrease in tangible fixed assets

AMERICAN VIETNAMESE BIOTECH INC

4F, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan Phu Ward, District 7, Ho Chi Minh City

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

	Machinery and equipment	Total
	VND	VND
ORIGINAL PRICE		
Balance as of 01/01/2024	64.268.202.914	64.268.202.914
Purchase during the period		-
Liquidation, sale	(14.922.812.105)	(14.922.812.105)
Balance as of 12/31/2024	49.345.390.809	49.345.390.809
DEPRECIATION VALUE		
Balance as of 01/01/2024	26.000.972.099	26.000.972.099
Depreciation during the year	(2.998.048.448)	(2.998.048.448)
Balance as of 12/31/2024	23.002.923.651	23.002.923.651
Residual value		
Balance as of 01/01/2024	38.267.230.815	38.267.230.815
Balance as of 12/31/2024	26.342.467.158	26.342.467.158

5.8.2 Increase or decrease of intangible fixed assets

	Copyright, patent	Software program	Other Fixed Assets	Total
	VND	VND	VND	VND
ORIGINAL PRICE				
Balance as of 01/01/2024	-	40.953.427.745	-	40.953.427.745
Purchased during the year	-	9.224.197.194	-	9.224.197.194
Balance as of 12/31/2024	-	50.177.624.939	-	50.177.624.939
DEPRECIATION VALUE				
Balance as of 01/01/2024	-	16.526.054.590	-	16.526.054.590
Depreciation during the ye	-	4.285.742.211	-	4.285.742.211
Balance as of 12/31/2024	-	20.811.796.801	-	20.811.796.801
Residual value				
Balance as of 01/01/2024	-	24.427.373.155	-	24.427.373.155
Balance as of 12/31/2024	-	29.365.828.138	-	29.365.828.138

AMERICAN VIETNAMESE BIOTECH INC

4F, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan Phu Ward, District 7, Ho Chi Minh City

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

5.9 Short-term trade payables

	31/12/2024		01/01/2024	
	Value	Repayable Amount	Value	Repayable Amount
	VND	VND	VND	VND
Phuong Dong techno.,jsc	-	-	232.965.920	232.965.920
TSG trading and services company limited	-	-	4.902.721.200	4.902.721.200
Duy Minh Equipment Company Limited	650.444.922	650.444.922	650.444.922	650.444.922
JWB CO.,LTD	298.643.120	298.643.120		-
- Payable to other entities	199.923.634	199.923.634	287.148.437	287.148.437
Add	1.149.011.676	1.149.011.676	6.073.280.479	6.073.280.479

5.10 Other Short-Term Payables

	31/12/2024		01/01/2024	
	Value	Repayment capacity	Value	Repayment capacity
	VND	VND	VND	VND
Dividends Payable	75.931.270.000	75.931.270.000	75.931.270.000	75.931.270.000
Add	75.931.270.000	75.931.270.000	75.931.270.000	75.931.270.000

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

5.11 Taxes and receivables, payable to the State

	Accounts Receivable 31/12/2024	Amount Payable 31/12/2024	Amount paid	Amount payable during the period	Accounts Receivable at the Beginning of the Year	Amount Payable at the Beginning of the Year
	VND	VND	VND	VND	VND	VND
Value Added Tax	-	861.689.793	14.932.156	876.621.949	-	-
Corporate income tax	-	584.861.115	200.000.000	784.861.115	-	-
Personal income tax	-	11.195.625	37.745.824	42.924.987	-	6.016.462
Other taxes	-	-	6.000.000	6.000.000	-	-
Add	-	1.457.746.533	258.677.980	1.710.408.051	-	6.016.462

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

5.12 Loans and financial leases**5.12.1 Short-term loans**

	31/12/2024		During the year		01/01/2024	
	Value VND	Number of debtors VND	Increase VND	Reduce VND	Value VND	Number of debtors VND
Long-term loan due	24.625.095.827	24.625.095.827	-	7.153.437.823	31.778.533.650	31.778.533.650
- An Binh Commercial Joint Stock Bank - Hanoi Branch	-	-	-	155.368.358	155.368.358	155.368.358
- Viet Capital Commercial Joint Stock Bank - Hanoi Branch	24.625.095.827	24.625.095.827	-	6.998.069.465	31.623.165.292	31.623.165.292
Add	24.625.095.827	24.625.095.827	-	7.153.437.823	31.778.533.650	31.778.533.650

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

5.14 Equity**Equity Fluctuation Reconciliation Table**

	Owner's equity		Capital surplus		Undistributed net profit		Total	
	VND		VND		VND		VND	
Balance as of 01/01/2023	1.311.056.500.000		(395.300.000)		215.505.662.285		1.526.166.862.285	
Profit and loss in the previous year	-		-		35.743.251.354		35.743.251.354	
Distribution of profit from the previous year	-		-		-		-	
Balance as of 12/31/2023	1.311.056.500.000		(395.300.000)		251.248.913.639		1.561.910.113.639	
Balance as of 01/01/2024	1.311.056.500.000		(395.300.000)		251.248.913.639		1.561.910.113.639	
Capital increase this year	-		-		-		-	
Profit this year	-		-		1.885.741.329		1.885.741.329	
Balance as of 12/31/2024	1.311.056.500.000		(395.300.000)		253.134.654.968		1.563.795.854.968	

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

5.15 Owner's Capital Contribution

	31/12/2024		01/01/2024	
	Quantity Share	Value VND	Quantity Share	Value VND
				Percentage %
Common stock	131.105.650	1.311.056.500.000	131.105.650	100,00%
Preferred Stock	-	-	-	0,00%
Add	131.105.650	1.311.056.500.000	131.105.650	100,00%
			1.311.056.500.000	100%

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

Share

	31/12/2024 VND	01/01/2024 VND
Owner's equity		
Beginning capital contribution	1.311.056.500.000	1.311.056.500.000
Year-end capital contribution	1.311.056.500.000	1.311.056.500.000
Dividends paid	75.924.090.000	-
	31/12/2024 Shares	01/01/2024 Shares
Number of shares registered for issuance	131.105.650	131.105.650
Number of shares sold to the public	131.105.650	131.105.650
Common stock	131.105.650	131.105.650
Number of shares outstanding	131.105.650	131.105.650
Common stock	131.105.650	131.105.650
<i>Outstanding shares par value (VND/share)</i>	<i>10.000</i>	<i>10.000</i>

6. ADDITIONAL INFORMATION FOR ITEMS PRESENTED IN THE CONSOLIDATED STATEMENT OF INCOME**Sales and service revenue****6.1.1 Sales and service revenue**

	This Quarter of the Year VND	This Quarter Last Year VND
Sales and service revenue	134.542.667.381	18.156.568.583
Add	134.542.667.381	18.156.568.583

6.2 Cost of goods sold

	This Quarter of the Year VND	This Quarter Last Year VND
Cost of goods sold and services rendered	125.187.344.799	16.381.254.875
Add	125.187.344.799	16.381.254.875

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

6.3 Financial revenue

	This Quarter of the Year <i>VND</i>	This Quarter Last Year <i>VND</i>
Interest on deposits and loans	102.280	160.093
Dividends distributed	5.000.000.000	12.000.000.000
Add	5.000.102.280	12.000.160.093

6.4 Financial costs

	This Quarter of the Year <i>VND</i>	This Quarter Last Year <i>VND</i>
Interest, other financial costs	1.631.781.902	1.036.262.771
Provision for impairment of trading securities and investment losses	(44.596.666.175)	(2.305.050.885)
Add	(42.964.884.273)	(1.268.788.114)

6.5 Cost of sales

	This Quarter of the Year <i>VND</i>	This Quarter Last Year <i>VND</i>
staff costs	66.666.663	-
Outsourcing service costs	7.041.645	-
Add	73.708.308	-

6.6 Business management costs

	This Quarter of the Year <i>VND</i>	This Quarter Last Year <i>VND</i>
Employee costs	1.251.961.570	778.626.679
Office supplies expenses	2.954.543	7.340.908
Fixed asset depreciation costs	1.498.107	1.498.107
Provision expenses	-	(22.550.844)
Outsourcing service costs	1.035.250.931	343.089.272
Other cash expenses	-	26.350.964
Add	2.291.665.151	1.134.355.086

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

6.7 Other income

	This Quarter of the Year	This Quarter Last Year
	VND	VND
Other income	3.924.305.575	(2)
Add	3.924.305.575	(2)

6.8 Other costs

	This Quarter of the Year	This Quarter Last Year
	VND	VND
Other costs	4.000.000	113.851.812
Add	4.000.000	113.851.812

7. OTHER INFORMATION

7.1 Transactions and Balances with Related Parties Related parties of the Company include key management personnel, individuals related to key management personnel, and other related entities.

7.1.1 List of Related Parties with Transactions and Balances with the Company during the Year

Related Party	Relationship
Viet My Hospital Investment JSC. Payment for purchases	Subsidiary Company
Golab Phap Van test center jsc	Associate Company
Huu Nghi Medicare clinic Jsc	Associate Company
Ninh Binh Medicare clinic Jsc	Associate Company

7.1.2 Business with stakeholders

	This Quarter of the Year	This Quarter Last Year
	VND	VND
Transactions with key management personnel		
Income of the board of directors		
Dang Nhi Nuong - Director	60.000.000	60.000.000

The company has no transactions and balances receivable/payable with key management personnel.

7.1.3 Transactions and Balances with Related Parties

NOTES TO SEPARATE FINANCIAL STATEMENTS

Quarter IV 2024

	This Quarter of the Year	This Quarter Last Year
	VND	VND
Viet My Hospital Investment JSC. Payment for purchases	2.835.000.000	15.905.000.000
Golab Phap Van test center jsc purchases	242.000.000	-
Huu Nghi Medicare clinic Jsc purchases	244.200.000	-
Ninh Binh Medicare clinic Jsc purchases	42.900.000	-

7.2 Comparative figures The comparative figures on the Separate Balance Sheet and corresponding notes are the figures of the Separate Financial Statements for the fiscal year ended December 31, 2023 audited by TTP Auditing Company Limited. The figures on the Income Statement, Cash Flow Statement and corresponding notes are the figures of the Company's Separate Financial Statements 7.3 Information on ongoing operations There are no significant events that could cast significant doubt on the Company's ability to continue as a going concern and the Company has no intention or need to cease operations or reduce the scale of its operations. . 7.4 Events occurring after the balance sheet date The Board of Directors of the Company affirms that, in the opinion of the Board of Directors, in all material respects, there have been no unusual events occurring after the balance sheet date that would affect the financial situation and operations of the Company that require adjustment or presentation in this interim financial report.



Dang Nhi Nuong
Director

Ho Chi Minh City January 24 , 2025

Le Thi Viet Ha
Chief Accountant

Nguyen Minh Hoa
The chartist